Doing some research...
Statement
Assets, liabilities and equity aligned across the annual filing history, in USD millions.
Assets
+6.5% YoYReported for FY 2025
Liabilities
+2.5% YoYReported for FY 2025
Equity
+9.4% YoYReported for FY 2025
Equity mix
+1.6 ppEquity share of the capital base
Table view
Balance sheet, reported dollar amounts — FY 2025
Every figure is the balance as filed. Each filing badge opens the SEC index page for that fiscal year.
Structure
Assets plotted against the liabilities and equity stack, so you can see how the balance sheet is financed.
Liabilities and equity stack to the capital base; assets are the dashed reference line.
Composition
The same split read as a share of total capital rather than in absolute dollars.
Percentages are measured against total capital for each fiscal year.
Trend
How assets, liabilities and equity have moved across the annual balance sheet window.
Switching between bar and line keeps the selected year order.
Commentary
This explanation uses an earlier data snapshot or evidence version. Compare its generation date with the current filing figures.
Earlier AI snapshot · Generated May 28, 2026. The filing-backed figures above are the current source of truth.
Abbott Laboratories’ balance sheet shows a generally strengthening financial position over the five-year period. Total assets were relatively stable from 2021 to 2023, moving from $75.2 billion to $73.2 billion, before rising more meaningfully in 2024 and 2025 to $81.4 billion and $86.7 billion, respectively. This late-period asset growth suggests expansion in the business base, whether through operating growth, acquisitions, or higher working capital/other asset buildup. In an industry like healthcare and medical devices, a steadily expanding asset base can support R&D, manufacturing capacity, and global commercialization. Liabilities trended downward overall, falling from $39.4 billion in 2021 to $34.6 billion in 2023, then remaining fairly stable at $33.8 billion in 2024 and ticking up slightly to $34.6 billion in 2025. The decline in liabilities alongside rising assets is a favorable signal, indicating improved balance-sheet flexibility and potentially lower leverage pressure. Stockholders’ equity increased every year, from $35.8 billion in 2021 to $52.1 billion in 2025, with especially strong growth in 2024 and 2025. Overall, Abbott appears to have materially strengthened its capital structure over the period, with equity growth outpacing liability growth and supporting a more resilient financial profile.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.